Baseline characteristics of the patients with mannose binding lectin (MBL) deficiency and patients without MBL deficiency in the microbiome subcohort study. GOLD class was calculated based on the 2011 guidelines. p Values were calculated through pairwise comparisons by T test for parametrical data and Mann-Whitney U test for non-parametrical data
| MBL deficient genotypes | MBL non-deficient genotypes | p Value | |
| Demographics and major comorbidities | |||
| N | 34 | 107 | |
| Age, years (SD) | 72.8 (±7.3) | 70.8 ± (8.2) | 0.2 |
| Age at diagnosis, years (SD) | 59.5 (±9.1) | 60.2 (±11.9) | 0.8 |
| Male gender (%) | 22 (64.7) | 67 (62.6) | 0.8 |
| Active smokers (%) | 7 (20.6) | 21 (19.6) | 0.9 |
| Cigarette smoking by pack years (SD) | 45.1 (±29.9) | 41.7 (±28.9) | 0.6 |
| Body mass index (SD) | 28.2 (±5.3) | 28.1 (±5.6) | 0.9 |
| Myocardial Infarction (%) | 4 (12.1) | 12 (11.2) | 0.9 |
| CABG (%) | 3 (8.8) | 12 (11.2) | 0.7 |
| Angina (%) | 6 (18.2) | 24 (22.4) | 0.6 |
| Stroke (%) | 7 (20.6) | 6 (5.6) | 0.008 |
| Diabetes (%) | 5 (14.7) | 22 (20.6) | 0.4 |
| COPD characteristics | |||
| FEV1 per cent predicted (SD) | 65.0 (±19.4) | 72.1 (±20.7) | 0.08 |
| MRC Dyspnoea Score (SD) | 3.0 (±1.5) | 2.58 (±1.4) | 0.1 |
| Exacerbations per year (SD) | 1.5 (±1.5) | 1.9 (±1.9) | 0.3 |
| Blood eosinophils >2% (%) | 16 (47.1) | 70 (65.4) | 0.06 |
| GOLD Score | 0.6* | ||
| A (%) | 2 (5.9) | 15 (14.0) | – |
| B (%) | 14 (41.2) | 38 (35.5) | – |
| C (%) | 2 (5.9) | 4 (3.7) | – |
| D (%) | 16 (47.1) | 50 (46.7) | – |
| SGRQ (SD) | 47.8 (±23.3) | 39.7 (±22.6) | 0.07 |
| On LTOT (%) | 0 (0) | 5 (4.7) | 0.2 |
| Medications | |||
| ICS/LABA (%) | 22 (64.7) | 62 (57.9) | 0.5 |
| LABA alone (%) | 3 (8.8) | 13 (12.1) | 0.6 |
| LAMA (%) | 19 (55.9) | 51 (47.7) | 0.4 |
| Mucolytic (%) | 7 (20.6) | 10 (9.3) | 0.08 |
| Aspirin (%) | 10 (29.4) | 27 (25.2) | 0.6 |
| β blocker (%) | 5 (14.7) | 13 (12.1) | 0.7 |
| Statin (%) | 20 (58.8) | 56 (52.3) | 0.5 |
| ACE inhibitor (%) | 7 (20.6) | 30 (28.0) | 0.4 |
| Clopidogrel (%) | 3 (8.8) | 7 (6.5) | 0.7 |
*indicates Χ2 test across all four GOLD groups.
CABG, coronary artery bypass graft; GOLD, Global Obstructive Lung Disease; ICS, inhaled corticosteroids; LABA, long-acting β agonist; LAMA, long-acting muscarinic antagonist; LTOT, long-term oxygen therapy; SGRQ, St George’s Respiratory Questionnaire.